The Lancet Diabetes & Endocrinology
Publisher: Elsevier · ISSN 2213-8587 · 42 articles
- Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial
- Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study
- Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case–control study
- Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial
- Hypoparathyroidism: translating science from the laboratory to the clinic
- From adiposity to multisystem morbidity: the case for weight loss as disease modification
- Disease modification outcomes in type 2 diabetes: a modified Delphi
- Presentation, management, and outcomes of ectopic Cushing syndrome: an international, multicentre, retrospective, cohort study
- Signals: The Inside Story of Our Hormones, Saira Hameed. Faber & Faber (2026), 326, £20·00, ISBN: 9780571389773
- Diagnosing diabetes: the earlier the better
- Efficacy and safety of co-administered cagrilintide–semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial
- The right dose, not the highest dose: rethinking obesity pharmacotherapy